Navigation Links
Data Trol™ Abnormal Control Serum

ProductsData Trol™ Abnormal Control Serum
Company ThermoFisher Scientific
Item Data Trol™ Abnormal Control Serum
Features 
  • Data Trol™ Abnormal Control Serum is intended for monitoring the accuracy and precision of commonly used clinical chemistry assays.
  • It is for in vitro diagnostic use only.
  • Provided in a 10 x 5ml lyophilized format, the control offers up to ten days stability at 2 8°C once reconstituted.
Description Data Trol™ Abnormal Control Serum is intended for monitoring the accuracy and precision of commonly used clinical chemistry assays. It is for in vitro diagnostic use only. Provided in a 10 x 5ml lyophilized format, the control offers up to ten days stability at 2 8°C once reconstituted. The control is to be used in accordance with the directions accompanying the assay procedure being used. While following these directions, the control serum is to be treated in the same manner a patient specimen would be treated. The results obtained for the control are to be compared with the assigned values given in the Assay Data section of the insert. An Evaluation made by the standard statistical technique determines if the procedure is within control limits.
Info ThermoFisher Scientific
Customer Service: (800) 637-3717
Web site: http://www.thermofisher.com/global/en/home.asp

Related medicine products :

1. Data Trol™ Normal Control Serum
2. Genomic Microarray Analysis for Constitutional Abnormalities
3. Endoalpha Centralized O.R. Control System
4. Cruise Control
5. US Autoflow Single Chamber Stackable Water-Jacketed CO2 Inc.w/ Humidity Display and Control
6. Fluid Control 2203
7. Flow Controller
8. Duet Diabetes Control System
9. Hemo_Control
10. Macro-Vue RPR (Rapid Plasma Reagin) Control Card
11. Macro-Vue RPR (Rapid Plasma Reagin) Control Cards
Solid 16 mm blades. Self-locking mechanism. Dull finish....
Fenestrated 16 mm blades. Self-locking mechanism. Dull finish....
... Kawesch-Lancaster Lasik speculum has wide ... to provide clearance for the ... retract the lids and lashes ... the microkeratome. The blades are ...
Adjustable wire speculum with 17 mm open blades. Lid tension adjustable throughout procedure with thumb screw control. Angled 45 degrees....
Medicine Products:
(Date:7/30/2014)... news of an Ohio teen who died of a ... the normally well-tolerated and mass-consumed substance. To help prevent ... much caffeine, scientists are reporting progress toward a rapid, ... stimulant in most beverages and even breast milk. Their ... Food Chemistry . , Mani Subramanian and colleagues note ...
(Date:7/30/2014)... Los Angeles, CA (PRWEB) July 30, 2014 ... Ghasri, now offers comprehensive cosmetic dental treatments that can ... office, Sunset Plaza Dental. Healthy teeth and gums form ... affect a person’s smile. While minor chips, misshapen teeth ... can all detract from a smile’s appearance. The right ...
(Date:7/30/2014)... 2014 All the children at Father’s ... rejection, abuse and exploitation tend to mar their respective ... and dejection. Quality youth development has underpinnings in a ... boosts confidence and in the foreseeable future, would assist ... light that the mere presence of Foundation members in ...
(Date:7/30/2014)... WEDNESDAY, July 30, 2014 (HealthDay News) -- ,Middle-aged adults ... twice as likely as others to develop severe memory ... The British researchers said their findings could help ... might benefit from help for problem drinking. "We ... and levels of current alcohol consumption -- that understanding ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 We know pregnancy ... to peanut butter and ice cream—but the latest episode of ... MDs , just posted online, has a recipe that is ... a James Beard Award-winning chef serves up an easy recipe ... is the executive chef at Rasika, which was named one ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 2Health News:Los Angeles Cosmetic Dentist, Dr. Poneh Ghasri, Now Offers Comprehensive Cosmetic Dental Treatments 3Health News:The Edusei Foundation Donates Food and Assorted Items to the Fathers’ Home Care Ministries in Takoradi, Ghana 2Health News:Adults Who've Abused Alcohol May Be at Risk for Memory Problems 2Health News:What to Eat When You’re Expecting 2
... Duke University Medical Center researchers, African-Americans have a notably ... hepatitis C than non-Hispanic whites. ,The ... which is the journal for the members of the ... with hepatitis C (HCV) infections experience a reduced response ...
... A new study published in the Journal of Neurology, Neurosurgery ... during //two peak periods. Japanese researchers who conducted the study ... and 8am and 6pm and 8pm. ,The researchers examined ... was lowest during sleep. This may probably be due to ...
... Health Service Executive in Ireland is all set to offer ... overcrowding.// ,The Irish Examiner reports that hospitals may be ... the A&E crisis, where patients are made to wait for ... patients are not made to wait over 24 hours. Also ...
... University of Siena, researchers found that cartoons are twice as ... medical procedures, such as having a blood sample taken. ... Scatte Clinic divided 69 children, aged between 7 and 12, ... kids started watching TV cartoons at least two minutes before ...
... a little extra income can make a big difference in helping ... the upper end," said Meredith Minkler, an author of a report ... England Journal of Medicine. "We always knew there was a major ... that the middle class was at a substantial disadvantage to slightly ...
... west of Scotland; Inverclyde, is to be revamped.// ... and increase in the range of community-based services will ... ,An already existing ward at Inverclyde Royal Hospital ... Children's hospital services, therapy services currently provided by ...
Cached Medicine News:Health News:African-Americans Have A Reduced Response To Hepatitis C Treatment 2Health News:African-Americans Have A Reduced Response To Hepatitis C Treatment 3Health News:The higher the income the lower the disability rates! 2Health News:A new deal for childcare services given go-ahead 2
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... and NYSE: SNY ) today announced that ... people with hypercholesterolemia met their primary efficacy endpoint of ... cholesterol (LDL-C) at 24 weeks compared to placebo or ... PCSK9 (proprotein convertase subtilisin/kexin type 9). In ...
(Date:7/30/2014)... SAN DIEGO , July 30, 2014  Eisai ... announced today that an article based on post-hoc analyses from ... Weight Loss While on Lorcaserin, Diet, and Exercise as a ... the online issue of Obesity , the official peer ... analyses was to identify whether there is an early treatment ...
(Date:7/30/2014)... 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), ... its expertise in opioid antagonists, announced today that ... prominent international research and development foundation. ... research-based initiatives, including those addressing health issues. Lightlake ... delivery of naloxone that could widely expand its ...
Breaking Medicine Technology:Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 2Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 3Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 4Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 5Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 6Eisai and Arena Pharmaceuticals Announce Publication of Post-Hoc Analyses of Lorcaserin Phase 3 Clinical Trial Results in Obesity 7Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3